Zobrazeno 1 - 10
of 1 349
pro vyhledávání: '"Trastuzumab resistance"'
Autor:
Soo-Yeon Hwang, Kyung-Hwa Jeon, Hwa-Jong Lee, Inhye Moon, Sehyun Jung, Seul-Ah Kim, Hyunji Jo, Seojeong Park, Misun Ahn, Soo-Yeon Kwak, Younghwa Na, Youngjoo Kwon
Publikováno v:
eLife, Vol 13 (2024)
HER2 overexpression significantly contributes to the aggressive nature and recurrent patterns observed in various solid tumors, notably gastric cancers. Trastuzumab, HER2-targeting monoclonal antibody drug, has shown considerable clinical success; ho
Externí odkaz:
https://doaj.org/article/299cfce3e3f844a5afe06b7ebbe171b3
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Gastric cancer (GC) is a malignancy with poor prognosis and high heterogeneity. For HER2-positive, PD-L1 negative metastatic GC patients, chemotherapy plus trastuzumab is the first-line therapy. However, such patients soon acquired resistance to trea
Externí odkaz:
https://doaj.org/article/63758ce7d30040898acd93cd8a43bce0
Autor:
Ningjun Duan, Yijia Hua, Xueqi Yan, Yaozhou He, Tianyu Zeng, Jue Gong, Ziyi Fu, Wei Li, Yongmei Yin
Publikováno v:
Advanced Science, Vol 11, Iss 18, Pp n/a-n/a (2024)
Abstract Secondary trastuzumab resistance represents an evolutionary adaptation of HER2‐positive breast cancer during anti‐HER2 treatment. Most current studies have tended to prioritize HER2 and its associated signaling pathways, often overlookin
Externí odkaz:
https://doaj.org/article/e14eb688c2e34550b89313acb25395d1
Autor:
Chidiebere U. Awah, Joo Sun Mun, Aloka Paragodaarachchi, Baris Boylu, Martin Nzegwu, Hiroshi Matsui, Olorunseun Ogunwobi
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Non-small cell lung cancer (NSCLC) caused more deaths in 2017 than breast cancer, prostate, and brain cancers combined. This is primarily due to their aggressive metastatic nature, leading to more fatal rates of cancer patients. Despite this conditio
Externí odkaz:
https://doaj.org/article/d0be878fbec7454e8fe5d7d025ee83e3
Autor:
Jun Cao, Yuee Teng, Huiping Li, Lili Zhang, Quchang Ouyang, Weimin Xie, Yueyin Pan, Zhenchuan Song, Xiaoling Ling, Xiaohong Wu, Jingwei Xu, Li Li, Liping Ren, Hong Wang, Dongxian Zhou, Jing Luo, Xichun Hu
Publikováno v:
BMC Medicine, Vol 21, Iss 1, Pp 1-10 (2023)
Abstract Background Patients with human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer and primary resistance to trastuzumab have a poor clinical outcome and lack good evidence to inform clinical decision. This study invest
Externí odkaz:
https://doaj.org/article/bdb8e110b7b14f79b5c021294f404095
Autor:
Soo-Yeon Hwang, Seojeong Park, Hyunji Jo, Seung Hee Seo, Kyung-Hwa Jeon, Seojeong Kim, Ah-Reum Jung, Chanju Song, Misun Ahn, Soo Yeon Kwak, Hwa-Jong Lee, Motonari Uesugi, Younghwa Na, Youngjoo Kwon
Publikováno v:
Journal of Advanced Research, Vol 47, Iss , Pp 173-187 (2023)
Introduction: HER2 overexpression induces cancer aggression and frequent recurrences in many solid tumors. Because HER2 overproduction is generally followed by gene amplification, inhibition of protein–protein interaction (PPI) between transcriptio
Externí odkaz:
https://doaj.org/article/c514c7b5d10c489d80d09349a306cdd7
Autor:
Asiye Busra Boz Er
Publikováno v:
Biology, Vol 13, Iss 6, p 429 (2024)
HER2-positive breast cancer, characterised by overexpressed HER2 levels, is associated with aggressive tumour behaviour and poor prognosis. Trastuzumab is a standard treatment; however, approximately 50% of patients develop resistance within one year
Externí odkaz:
https://doaj.org/article/794dba71b5d84e0ba37c18adf5177c84
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Redox Biology, Vol 67, Iss , Pp 102896- (2023)
Trastuzumab notably improves the outcome of human epidermal growth factor receptor 2 (HER2)-positive breast cancer patients, however, resistance to trastuzumab remains a major hurdle to clinical treatment. In the present study, we identify a circular
Externí odkaz:
https://doaj.org/article/8ac36f5a989148d1aa8e0f5dfb6ab3b4
Autor:
Xinlin Liu, Linli Luan, Xi Liu, Dingwen Jiang, Junwen Deng, Jiazhen Xu, Yang Yuan, Jiyao Xing, Bingguan Chen, Dongming Xing, Haiming Huang
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Human epithelial growth factor receptor-2 (HER2) plays an oncogenic role in numerous tumors, including breast, gastric, and various other solid tumors. While anti-HER2 therapies are approved for the treatment of HER2-positive tumors, a necessity pers
Externí odkaz:
https://doaj.org/article/31cb72e90bb9468aacdde98b705a3c3b